Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis. 2025 Jul 7;31(7):1876-1890. doi: 10.1093/ibd/izae253.
Inflamm Bowel Dis. 2025.
PMID: 39448057
Free PMC article.
Clinical Trial.
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.
Lee SD, Ehrlich AC, Pellanda P, Kaiser C, Todd K, Moses R, Walsh A.
Lee SD, et al.
Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003407. Online ahead of print.
Am J Gastroenterol. 2025.
PMID: 40071779
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.